BioDelivery Sciences upgraded to Overweight from Neutral at Piper Jaffray Piper Jaffray upgraded BioDelivery Sciences citing the competitive position of the company's chronic pain treatment BBCP. The firm raised its price target for shares to $8 from $5.
Summer Street still feels Endo could acquire BioDelivery Sciences Summer Street reiterated its belief that Endo (ENDP) could acquire BioDelivery Sciences (BDSI), its partner on multiple products. The firm says scripts for BioDelivery's Bunavail continue to trend in the right direction. It reiterates a Buy rating on the stock with a $25 price target.